Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Definium Therapeutics Earnings Call: Key Takeaways

Definium Therapeutics reported positive Phase 3 results for DT120 in GAD and MDD, maintaining a strong $1.05 billion cash position to fund operations through 2030 while preparing for a 2027 NDA filing.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceHigh confidence in clinical evidence and commercial strategy for DT120 ODT.
Demand VisibilityTargeting millions of patients with GAD and MDD; no new GAD treatments.
Margin TrendsOperating expenses consistent with expectations; spending moderated after key clinical readouts.
Op. LeverageFinancial strength allows decisive investment in launch preparation without compromising quality.
Pricing PowerAnticipated pricing corridor between $30,000 and $75,000 based on Spravato benchmarks.
Segment GrowthDT120 Phase 3 met primary endpoints in GAD and MDD studies.
New ClientsEngaging interventional psychiatry providers; hired new Head of Patient Advocacy.
Capex & Debt$1.05 billion in cash and investments as of September 30, 2026.
RegulatoryTwo FDA breakthrough therapy designations; NDA filing targeted for H1 2027.
CommentaryFocusing on a supervised treatment model and building commercial infrastructure for launch.
New LaunchesPlanned Phase 3 Haven study in PTSD and DT402 for ASD.

Growth

Q3 2026 net loss narrowed to $51 million from $67.3 million year-over-year; R&D expenses rose to $46.1 million.

Outlook

NDA filing planned for H1 2027; cash runway extends into 2030 with $1.05 billion available.

Risks

Management avoided specific details on pre-NDA meeting outcomes and the exact filing strategy for MDD indications.

Source

The company's earnings call, NASDAQ: DFTX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Definium Therapeutics, Inc.: key numbers

Share price
$29.38Close, Nov 17
Market cap
$4.02B
Shares outstanding
136.9MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Definium Therapeutics, Inc.

All →
4:16 PM ET 10-Q
Financial Results ▶ Call

Definium Therapeutics Q3 2026 Results: Net Loss of $51M, Loss Narrows

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based treatments like DT120 (LSD) and DT402 (MDMA) for psychiatric disorders. As of November 2, 2026, the company had 136,899,935 common shares outstanding and is currently conducting Phase 3 clinical programs for generalized anxiety disorder and major depressive disorder.

Key figure
Net loss $51M
4:11 PM ET 8-K
Financial Results

Definium Therapeutics Financial Results

Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.

Term
Q3 2026

“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”

Rob Barrow, Chief Executive Officer

“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”

Rob Barrow, Chief Executive Officer
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics CFO Brandi Roberts Sells $123K of Stock

Brandi Roberts, CFO, sold 3,377 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $123K in total on Sep 25, 2026. Shares held after the trade: 394,528 (-0.8%).

Value
$123K
Shares
3,377
Price
$36.57
Role
CFO
Holding change
-0.8%
Trade date
Sep 25, 2026
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics CLO Mark Sullivan Sells $514K of Stock

Mark Sullivan, CLO, sold 14,051 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $514K in total on Sep 25, 2026. Shares held after the trade: 494,228 (-2.8%).

Value
$514K
Shares
14,051
Price
$36.57
Role
CLO
Holding change
-2.8%
Trade date
Sep 25, 2026
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics Chief Commercial Officer Matthew T. Wiley Sells $113K of Stock

Matthew T. Wiley, Chief Commercial Officer, sold 3,097 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $113K in total on Sep 25, 2026. Shares held after the trade: 359,036 (-0.9%).

Value
$113K
Shares
3,097
Price
$36.57
Role
Chief Commercial Officer
Holding change
-0.9%
Trade date
Sep 25, 2026
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics CEO Robert Barrow Sells $1.15M of Stock

Robert Barrow, CEO, sold 31,550 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $1.15M in total on Sep 25, 2026. Shares held after the trade: 2,213,090 (-1.4%).

Value
$1.15M
Shares
31,550
Price
$36.57
Role
CEO
Holding change
-1.4%
Trade date
Sep 25, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.